Author: Fiona Craig

Pennant International (LSE:PEN) has strengthened its position in the U.S. defence market after securing another sale of its Auxilium systems support software through its strategic partnership with Siemens Digital Industries Software. The agreement represents the second customer win delivered through the Siemens sales channel this year.

The latest contract involves a major U.S. defence customer and provides further evidence of growing commercial demand for Pennant’s Auxilium platform. It also supports the company’s strategy of using indirect sales partnerships to broaden the software’s reach within complex and highly regulated defence environments.

Alongside the new contract, Pennant reported that annual recurring revenue generated by Auxilium has increased to approximately £2.9 million. This compares with £2.4 million at the end of FY2025 and represents a new record for the group.

The increase in recurring revenue supports Pennant’s ongoing transition towards a business model with a greater contribution from software and services. Expanding this portion of the revenue base has the potential to improve visibility over future income while reducing reliance on individual project-based contracts.

The latest Auxilium sale also strengthens Pennant’s presence in mission-critical defence and aerospace support markets, where customers require sophisticated tools to manage increasingly complex equipment, logistics and maintenance requirements.

Pennant’s broader financial performance nevertheless remains challenging, with declining revenue and widening losses weighing on its outlook. Cash generation has remained modest and inconsistent. In contrast, technical indicators have recently been stronger, with the shares trading above major moving averages, although a high relative strength index points to the possibility of overbought conditions. Valuation measures also remain difficult to assess conventionally while the company is loss-making and does not provide a dividend yield.

About Pennant International

Pennant International Group PLC is a technology-focused provider of systems support software, technical services and training solutions for customers operating in aerospace, defence, rail and other safety-critical industries, including shipping, nuclear and space.

Headquartered in Cheltenham, the group operates across the UK, North America and Asia-Pacific. Its strategy is increasingly focused on generating higher-margin, recurring and repeatable revenues from software, technical services and specialist training solutions.

Pennant’s Auxilium software suite provides integrated product and logistics support capabilities designed to help organisations manage complex equipment information, improve asset availability and comply with relevant industry standards.

The group’s technical services operations provide consultancy, maintenance, support and bespoke development, while its training systems division develops hardware, software and virtual training solutions for personnel operating and maintaining aircraft, naval vessels and land-based platforms in highly regulated markets.

Windar Photonics (LSE:WPHO) has opened a retail share offer through the BookBuild platform as part of a wider fundraising initiative ahead of the planned resumption of trading in its shares on AIM. The company is seeking to raise up to £200,000 by issuing as many as 4,000,000 new ordinary shares at 5 pence each.

The offer price represents a substantial discount to the company’s final closing share price before trading was suspended on AIM. Investors participating in the retail offer will also receive a three-year warrant for each new share subscribed, exercisable at 10 pence per share.

Participation is restricted to existing Windar Photonics shareholders in the UK and is being made available through eligible intermediaries participating in the BookBuild platform. The structure is intended to give retail shareholders an opportunity to participate alongside investors involved in the company’s separate placing and direct subscription.

Completion of the retail offer is dependent on several conditions. These include successful completion of the placing, publication of Windar Photonics’ audited accounts for 2025, the lifting of the current AIM trading suspension and admission of the newly issued shares to trading. Admission is currently targeted for 28 August 2026.

By including a dedicated retail component in the broader capital raise, Windar Photonics is seeking to provide existing individual shareholders with access to the fundraising while securing additional capital for its operations. The transaction also forms part of the steps being taken by the company towards restoring trading in its shares.

The company is using applicable regulatory exemptions governing public share offers to conduct the retail fundraising. Together with the institutional placing and direct subscription, the structure is designed to maintain participation across management, institutional investors and the existing retail shareholder base.

Windar Photonics continues to face financial and market-related challenges, with weak underlying financial performance and bearish technical indicators weighing on its outlook. Negative valuation metrics add further pressure, while recent strategic and corporate developments provide some positive momentum but have yet to outweigh the company’s broader financial and technical difficulties.

About Windar Photonics

Windar Photonics plc is a UK-listed wind energy technology company specialising in LiDAR-based systems used to measure wind conditions and optimise wind turbine performance.

Its technology is aimed at operators of both onshore and offshore wind farms, providing sensor-based solutions intended to improve turbine efficiency and increase energy generation. The company targets both existing wind turbine fleets and new installations as the global renewable energy sector continues to expand.

AstraZeneca (LSE:AZN) has priced a €2.55 billion multi-tranche Eurobond offering through its finance subsidiary, with the notes fully and unconditionally guaranteed by the parent company. The transaction gives the pharmaceutical group additional long-term funding across a range of maturities between 2030 and 2038.

The bonds have been issued under AstraZeneca’s Euro Medium Term Note programme and carry coupons ranging from 3.402% to 4.169%. The securities are expected to be listed on the London Stock Exchange, providing the company with further access to European debt capital markets.

AstraZeneca said the net proceeds will be used for general corporate purposes. The absence of a specific acquisition or project linked to the fundraising suggests the transaction forms part of the group’s broader balance sheet and liquidity management strategy.

The offering was arranged by a group of major international banks acting as joint bookrunners. By extending its funding profile through longer-dated euro-denominated debt, AstraZeneca is reinforcing its financial flexibility as it continues to invest in research and development, product launches and commercial operations across its global markets.

The company’s broader outlook remains supported by solid underlying profitability, reiterated guidance and continued momentum across its drug development pipeline. These strengths are partly offset by less favourable technical signals, with the shares trading below several major moving averages, as well as mixed cash conversion and an increase in net debt during the first half.

Valuation also remains relatively demanding compared with more discounted areas of the market, reflecting expectations for continued earnings and pipeline growth rather than a deep-value investment case.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, UK. The group focuses on the discovery, development and commercialisation of prescription medicines across several major therapeutic areas.

Its portfolio includes treatments in Oncology, Rare Disease and BioPharmaceuticals, with the latter covering Cardiovascular, Renal & Metabolism and Respiratory & Immunology. AstraZeneca’s medicines are sold in more than 125 countries and reach millions of patients worldwide.

Its broad international footprint, established commercial platform and extensive research pipeline support the company’s ability to access global capital markets when funding long-term strategic, operational and investment requirements.

The Smarter Web Company PLC (LSE:SWC) has confirmed that Jesse Myers will leave the business with effect from 1 September 2026, while stressing that the departure will not result in any change to its existing Bitcoin Treasury Policy.

Chief executive Andrew Webley said the company remains committed to delivering its stated strategy and longer-term ambitions. Oversight of the Bitcoin treasury approach will continue to sit with the board, providing continuity in the company’s strategic direction following Myers’ exit.

The Smarter Web Company reiterated that a significant proportion of its treasury reserves and surplus cash is held in Bitcoin. While management sees potential strategic advantages from this approach, the company has also highlighted the substantial risks associated with holding cryptoassets, including sharp price volatility and the relatively limited regulatory framework surrounding the sector.

The company has emphasised that purchasing its shares should not be regarded as either a direct investment or a proxy investment in Bitcoin. However, its exposure to the cryptocurrency means movements in the Bitcoin price could have a material impact on its financial position.

Other risks include possible restrictions affecting cryptocurrency trading, wider market volatility and security-related threats associated with digital assets. The company has advised prospective investors to consider these factors carefully when assessing an investment in the business.

From a financial perspective, the outlook continues to be constrained by persistent negative operating and free cash flow, together with uneven underlying operating performance, despite improvements to the balance sheet. Technical indicators have been more constructive, with the share price trading above important moving averages and the MACD remaining positive. A low price-to-earnings ratio also suggests a relatively modest valuation, although these factors are balanced by continued cash consumption and operational uncertainty.

About The Smarter Web Company PLC

The Smarter Web Company PLC provides web design, website development and digital marketing services. Its business model typically generates revenue through upfront development fees, annual hosting charges and optional recurring monthly marketing services.

The company is pursuing a combination of organic expansion and acquisitions as it seeks to grow its customer base and increase recurring revenues. Bitcoin also forms part of its wider corporate strategy, with the business accepting the cryptocurrency as a payment method and holding Bitcoin under its dedicated treasury policy.

Solvonis Therapeutics (LSE:SVNS) has conditionally secured £1.3 million through a share placing as the biopharmaceutical company looks to fund further development of its central nervous system pipeline. The fundraising also introduces a new UK institutional investor to the shareholder register, while Turner Pope Investments has been appointed as the company’s corporate broker.

The placing comprises 1,083,333,333 new shares issued at a discount. Admission of the placing shares and associated fee shares to trading on the Main Market is expected on or around 28 August, after which Solvonis will have an enlarged issued share capital of approximately 7.9 billion shares.

Proceeds from the fundraising are earmarked for several clinical and development milestones. These include the potential expansion of the Phase 3 trial of SVN-001, Solvonis’ treatment candidate for alcohol use disorder, to selected clinical sites in the European Union.

Funding will also support IND-enabling activities and preparations for a Phase 2b programme in the United States for SVN-002, the company’s oral esketamine candidate. In addition, Solvonis plans to advance programme development for SVN-015, its NIDA-backed candidate targeting stimulant use disorders.

Part of the proceeds will be allocated to general working capital requirements. The fundraising is intended to provide additional financial resources as Solvonis progresses its clinical programmes while also strengthening its engagement with UK institutional investors.

The company continues to face financial challenges, including recurring losses, declining revenue in recent annual periods and ongoing cash consumption. These pressures are partly mitigated by relatively low levels of debt. From a technical perspective, the shares remain below major moving averages, while conventional valuation measures offer limited support given the negative price-to-earnings ratio and absence of dividend yield data.

About Solvonis Therapeutics

Solvonis Therapeutics plc is a late clinical-stage biopharmaceutical company developing novel small-molecule therapies for central nervous system conditions with significant unmet medical needs, with a particular emphasis on substance use disorders.

Its principal programmes include SVN-001 for severe alcohol use disorder and SVN-002, an oral esketamine candidate targeting moderate-to-severe alcohol use disorder in the United States. The company is also developing SVN-015, a discovery-stage programme focused on potential treatments for stimulant use disorders.

Talon Resources (LSE:TAR) is moving ahead with its first diamond drilling campaign at the Eagle Lake gold project in Ontario, using artificial intelligence-assisted targeting to help guide exploration. The North America-focused gold explorer is combining conventional geological work with machine learning technology as it seeks to sharpen drill targets and improve the efficiency of potential discoveries.

The company has completed planning and site preparations for an 11-hole drilling programme covering approximately 1,375 metres across four priority areas at Eagle Lake. The campaign was brought forward and expanded following encouraging results from the first phase of channel sampling.

MINML’s PRISM platform has ranked the Eagle Lake licence within the top percentile for gold prospectivity in Canada. Talon’s fully funded and permitted drilling programme will now test several of the highest-ranked areas, with the results expected to contribute to the company’s evolving geological model and inform its wider AI-supported exploration approach.

Drilling will focus on East Fornieri Bay, West Fornieri Bay, Cedar Trench and Moss Knoll. These areas have either produced high-grade gold results from channel sampling, contain notable historical drill intercepts or have received strong rankings from PRISM’s property-scale modelling.

The programme will include the twinning of selected historical drill holes alongside testing of newly identified zones. Through this work, Talon aims to verify earlier exploration results, reduce geological uncertainty and assess whether Eagle Lake has characteristics comparable with established gold-producing areas elsewhere in Canada.

About Talon Resources plc

Talon Resources plc is an AIM-listed gold exploration company targeting high-impact discovery opportunities across North America. Its principal asset is the Eagle Lake gold project in Ontario’s Wabigoon Subprovince, where the company holds a 90% interest in a land package containing multiple high-grade gold targets and further exploration potential.

The company is working with technology specialist MINML to incorporate machine learning-based prospectivity mapping into its exploration activities across the Wabigoon Subprovince. These tools are also being used to identify additional regional targets while Talon continues to assess other prospective gold opportunities across North America.

Talon’s exploration model combines established geological techniques with data-led targeting technology. By bringing together geoscientific information and advanced modelling, the company is seeking to improve targeting accuracy, make exploration more efficient and increase the potential for successful discoveries within its project portfolio.

Global crude steel production edged lower in July as declining output in China outweighed continued expansion across several other major steel-producing economies, according to Morgan Stanley.

Worldwide production decreased 0.3% year-over-year during July, leaving cumulative output 0.6% below the previous year’s level.

China was responsible for the overall contraction, with production falling 3.6% from July last year and 3.1% year-to-date. Excluding China, the picture was considerably stronger, with global output increasing 3.4% year-over-year and 2.4% since the beginning of the year.

US, India and Turkey Lead Growth Outside China

Production trends remained positive across a number of important steel markets.

India increased crude steel output by 1.9% year-over-year in July, taking year-to-date growth to 6.1%. US production climbed 4.4% from a year earlier and was 6.0% higher for the year so far.

Turkey delivered one of the strongest performances, with output rising 7.0% year-over-year and 7.9% year-to-date. South Korea also recorded solid growth of 6.4% and 2.7%, respectively.

Russia’s production recovered 3.3% compared with July last year, although output remained down 6.1% year-to-date. Japan recorded a modest 0.4% annual increase, while Brazil’s production was virtually unchanged with growth of just 0.1%.

Further Chinese Production Decline Indicated in August

China’s steel industry appears to have remained under pressure into August.

The China Iron and Steel Association’s month-to-date survey points to a 4.9% year-over-year reduction in output from Chinese mills, extending the weakness seen during July.

Despite lower domestic production, Chinese exports remain substantial. As of July, steel shipments from the country were running at an annualised pace of approximately 116 million tonnes.

The combination of weaker Chinese production and elevated export volumes remains an important factor for international steel markets and pricing.

European Steelmakers Report Improving Output

European production strengthened in July, with crude steel output across the EU27 increasing 3.8% year-over-year and moving 0.4% higher on a year-to-date basis.

Including the UK, European production advanced 3.5% from July last year, although cumulative output was unchanged.

Germany recorded growth of 3.0% year-over-year and a stronger 8.1% increase year-to-date. Italy’s production rose 4.2% annually and 3.6% for the year so far.

Elsewhere, Finland increased output by 13.0% from a year earlier, Sweden by 10.1% and Austria by 3.3%. France delivered a 12.5% year-over-year rebound, although its cumulative production remained 1.3% lower.

Several markets continued to struggle. Year-to-date steel output was down 13.8% in Spain, 5.3% in the Netherlands, 6.1% in Poland and 18.0% in the UK.

EU Hot-Rolled Coil Spreads Move Well Above Historical Average

Improving conditions in parts of the European steel industry have been accompanied by stronger hot-rolled coil spreads.

EU HRC spreads have climbed to $464 per tonne, significantly above their long-term average of approximately $320 per tonne.

The increase provides a more supportive margin backdrop for European steelmakers, even as the global production picture remains divided between falling Chinese output and stronger activity across many markets outside China.